These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 15864584)

  • 41. Pretargetted imaging of colorectal cancer recurrences using an 111In-labelled bivalent hapten and a bispecific antibody conjugate.
    Chetanneau A; Barbet J; Peltier P; Le Doussal JM; Gruaz-Guyon A; Bernard AM; Resche I; Rouvier E; Bourguet P; Delaage M
    Nucl Med Commun; 1994 Dec; 15(12):972-80. PubMed ID: 7715897
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Optimizing bispecific antibody pretargeting for use in radioimmunotherapy.
    Sharkey RM; Karacay H; Richel H; McBride WJ; Rossi EA; Chang K; Yeldell D; Griffiths GL; Hansen HJ; Goldenberg DM
    Clin Cancer Res; 2003 Sep; 9(10 Pt 2):3897S-913S. PubMed ID: 14506188
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pretargeted radioimmunotherapy of colorectal cancer metastases: models and pharmacokinetics predict influence of the physical and radiochemical properties of the radionuclide.
    Frampas E; Maurel C; Remaud-Le Saëc P; Mauxion T; Faivre-Chauvet A; Davodeau F; Goldenberg DM; Bardiès M; Barbet J
    Eur J Nucl Med Mol Imaging; 2011 Dec; 38(12):2153-64. PubMed ID: 21858527
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pretargeted radioimmunotherapy with a single-chain antibody/streptavidin construct and radiolabeled DOTA-biotin: strategies for reduction of the renal dose.
    Förster GJ; Santos EB; Smith-Jones PM; Zanzonico P; Larson SM
    J Nucl Med; 2006 Jan; 47(1):140-9. PubMed ID: 16391198
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pretargeted immuno-positron emission tomography imaging of carcinoembryonic antigen-expressing tumors with a bispecific antibody and a 68Ga- and 18F-labeled hapten peptide in mice with human tumor xenografts.
    Schoffelen R; Sharkey RM; Goldenberg DM; Franssen G; McBride WJ; Rossi EA; Chang CH; Laverman P; Disselhorst JA; Eek A; van der Graaf WT; Oyen WJ; Boerman OC
    Mol Cancer Ther; 2010 Apr; 9(4):1019-27. PubMed ID: 20354120
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Improved tumor selectivity of radiolabeled peptides by receptor and antigen dual targeting in the neurotensin receptor model.
    Hillairet De Boisferon M; Raguin O; Thiercelin C; Dussaillant M; Rostène W; Barbet J; Pélegrin A; Gruaz-Guyon A
    Bioconjug Chem; 2002; 13(3):654-62. PubMed ID: 12009958
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Clearance of injected radioactively labelled antibodies to tumour products by liposome-bound second antibodies.
    Keep PA; Searle F; Begent RH; Barratt GM; Boden J; Bagshawe KD; Ryman BE
    Oncodev Biol Med; 1983; 4(4):273-80. PubMed ID: 6601263
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Therapeutic advantage of pretargeted radioimmunotherapy using a recombinant bispecific antibody in a human colon cancer xenograft.
    Karacay H; Brard PY; Sharkey RM; Chang CH; Rossi EA; McBride WJ; Ragland DR; Horak ID; Goldenberg DM
    Clin Cancer Res; 2005 Nov; 11(21):7879-85. PubMed ID: 16278412
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Metastatic human colonic carcinoma: molecular imaging with pretargeted SPECT and PET in a mouse model.
    Sharkey RM; Karacay H; Vallabhajosula S; McBride WJ; Rossi EA; Chang CH; Goldsmith SJ; Goldenberg DM
    Radiology; 2008 Feb; 246(2):497-507. PubMed ID: 18227543
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pretargeted 177Lu radioimmunotherapy of carcinoembryonic antigen-expressing human colonic tumors in mice.
    Schoffelen R; van der Graaf WT; Franssen G; Sharkey RM; Goldenberg DM; McBride WJ; Rossi EA; Eek A; Oyen WJ; Boerman OC
    J Nucl Med; 2010 Nov; 51(11):1780-7. PubMed ID: 21051650
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Advantage of a residualizing iodine radiolabel in the therapy of a colon cancer xenograft targeted with an anticarcinoembryonic antigen monoclonal antibody.
    Stein R; Govindan SV; Hayes M; Griffiths GL; Hansen HJ; Horak ID; Goldenberg DM
    Clin Cancer Res; 2005 Apr; 11(7):2727-34. PubMed ID: 15814655
    [TBL] [Abstract][Full Text] [Related]  

  • 52. In vivo evaluation of pretargeted 64Cu for tumor imaging and therapy.
    Lewis MR; Wang M; Axworthy DB; Theodore LJ; Mallet RW; Fritzberg AR; Welch MJ; Anderson CJ
    J Nucl Med; 2003 Aug; 44(8):1284-92. PubMed ID: 12902420
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Two-step immunoscintigraphy for non-small-cell lung cancer staging using a bispecific anti-CEA/anti-indium-DTPA antibody and an indium-111-labeled DTPA dimer.
    Vuillez JP; Moro D; Brichon PY; Rouvier E; Brambilla E; Barbet J; Peltier P; Meyer P; Sarrazin R; Brambilla C
    J Nucl Med; 1997 Apr; 38(4):507-11. PubMed ID: 9098191
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Enhanced antitumor activity of combined pretargeted radioimmunotherapy and paclitaxel in medullary thyroid cancer xenograft.
    Kraeber-Bodéré F; Saï-Maurel C; Campion L; Faivre-Chauvet A; Mirallié E; Chérel M; Supiot S; Barbet J; Chatal JF; Thédrez P
    Mol Cancer Ther; 2002 Feb; 1(4):267-74. PubMed ID: 12467222
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Amplification targeting: a modified pretargeting approach with potential for signal amplification-proof of a concept.
    He J; Liu G; Gupta S; Zhang Y; Rusckowski M; Hnatowich DJ
    J Nucl Med; 2004 Jun; 45(6):1087-95. PubMed ID: 15181145
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Targeting BCL1 lymphoma with anti-idiotype antibodies: biodistribution kinetics of directly labeled antibodies and bispecific antibody-targeted bivalent haptens.
    Manetti C; Rouvier E; Gautherot E; Loucif E; Barbet J; Le Doussal JM
    Int J Cancer; 1997 Jun; 71(6):1000-9. PubMed ID: 9185704
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Galactosylated streptavidin for improved clearance of biotinylated intact and F(ab')2 fragments of an anti-tumour antibody.
    Marshall D; Pedley RB; Melton RG; Boden JA; Boden R; Begent RH
    Br J Cancer; 1995 Jan; 71(1):18-24. PubMed ID: 7529526
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pretargeting with labeled bivalent peptides allowing the use of four radionuclides: (111)In, (131)I, (99m)Tc, and (188)Re.
    van Schaijk FG; Oosterwijk E; Soede AC; Oyen WJ; McBride WJ; Griffiths GL; Goldenberg DM; Corstens FH; Boerman OC
    Clin Cancer Res; 2003 Sep; 9(10 Pt 2):3880S-5S. PubMed ID: 14506186
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A universal pretargeting system for cancer detection and therapy using bispecific antibody.
    Sharkey RM; McBride WJ; Karacay H; Chang K; Griffiths GL; Hansen HJ; Goldenberg DM
    Cancer Res; 2003 Jan; 63(2):354-63. PubMed ID: 12543788
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Evaluation of a complementarity-determining region-grafted (humanized) anti-carcinoembryonic antigen monoclonal antibody in preclinical and clinical studies.
    Sharkey RM; Juweid M; Shevitz J; Behr T; Dunn R; Swayne LC; Wong GY; Blumenthal RD; Griffiths GL; Siegel JA
    Cancer Res; 1995 Dec; 55(23 Suppl):5935s-5945s. PubMed ID: 7493374
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.